Novo Nordisk A/S engages in the research, development, manufacture, and marketing of pharmaceutical products. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in areas of haemophilia, growth disorders, and hormone replacement therapy. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Market Cap | 356.807 Billion | Shares Outstanding | 3.435 Billion | Avg 30-day Volume | 4.773 Million |
| P/E Ratio | 0.0 | Dividend Yield | 1.3512 | EPS | 20.79 |
| Price to Revenue | 0.0 | Debt to Equity | 0.4075 | EBITDA | 9.842 Billion |
| Price to Book Value | 0.0 | Operating Margin | 41.6506 | Enterprise Value | 0 |
| Current Ratio | 0.86 | EPS Growth | 0.152 | Quick Ratio | 0.425 |
| 1 Yr BETA | 0.7171 | 52-week High/Low | 105.69 / 59.02 | Profit Margin | 33.9183 |
| Operating Cash Flow Growth | 7.6066 | Free Cash Flow to Firm (FCFF) TTM | 4.063 Billion | Free Cash Flow to Equity (FCFE) TTM | 10.641 Billion |
| Altman Z-Score | 0.0 |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|---|---|---|---|
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-28 14:15:04 UTC | 5.07 | 0.25 | 5400000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-28 13:45:04 UTC | 5.0531 | 0.2669 | 4400000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-28 13:15:03 UTC | 5.0531 | 0.2669 | 4400000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-28 12:45:04 UTC | 5.0531 | 0.2669 | 4400000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 22:15:04 UTC | 5.0557 | 0.2643 | 5100000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 21:45:04 UTC | 5.0557 | 0.2643 | 5100000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 21:15:03 UTC | 5.0557 | 0.2643 | 5100000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 20:45:04 UTC | 5.0557 | 0.2643 | 5100000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 20:15:05 UTC | 5.0607 | 0.2593 | 5100000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 19:45:04 UTC | 5.0607 | 0.2593 | 5100000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 19:15:04 UTC | 5.0607 | 0.2593 | 5100000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 18:45:05 UTC | 5.0607 | 0.2593 | 5100000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 18:15:03 UTC | 5.0607 | 0.2593 | 5100000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 17:45:04 UTC | 5.0607 | 0.2593 | 5100000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 17:15:03 UTC | 5.0607 | 0.2593 | 5100000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 16:45:04 UTC | 5.0607 | 0.2593 | 5100000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 16:15:03 UTC | 5.0607 | 0.2593 | 5100000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 15:45:04 UTC | 5.0607 | 0.2593 | 4400000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 15:15:03 UTC | 5.0607 | 0.2593 | 4400000 |
| NOVO-NORDISK A-S-SPONS ADR NVO | 2023-11-27 14:45:03 UTC | 5.0503 | 0.2697 | 4400000 |
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|---|---|---|---|
| Weiss Strategic Interval Fund- Weiss Strategic Interval Fund | NVO | -8725.0 shares, $-869271.75 | 2022-09-30 | N-PORT |
| AQR Funds- AQR Alternative Risk Premia Fund | NVO | -2434.0 shares, $-221618.78 | 2023-09-30 | N-PORT |
| AQR Funds- AQR Multi-Asset Fund | NVO | -2747.0 shares, $-250117.82 | 2023-09-30 | N-PORT |
| Congress Person | Party | Chamber | Filing | Filing Date | Transaction Date | Security Type | Owner | Transaction | Amount | |
|---|---|---|---|---|---|---|---|---|---|---|
| Hon. Daniel Goldman | House | Filing | 2023-08-09 | 2023-07-12 | S | $100,001-$250,000 | ||||
| Hon. Daniel Goldman | House | Filing | 2023-08-04 | 2023-07-10 | S | $250,001-$500,000 |
